Sensei Biotherapeutics rakes in $28.5M to give cancer immunotherapies a push

Nicole DeFeudis

Editor

Less than a month after offering a glimpse at early clinical data for its lead cancer immunotherapy at virtual ESMO, Sensei Biotherapeutics has reeled in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sensei Biotherapeutics rakes in $28.5M to give cancer immunotherapies a push

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sen­sei Bio­ther­a­peu­tics rakes in $28.5M to give can­cer im­munother­a­pies a push

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sensei Biotherapeutics rakes in $28.5M to give cancer immunotherapies a push